CureLauncher has closed on a Series B round of funding worth $500,000.
The Bloomfield Hills-based startup that likes to refer to itself as the Wikipedia of clinical trials also closed on a half-million-dollar Series A last year. The Series B was led by Birmingham-based early stage venture capital firm
InkWell.
"It will help us grow fast," says
Steve Goldner, chairman & CEO of
CureLauncher. "It will add more talent to the team."
CureLauncher's software is a one-stop shop for people looking to participate in clinical trials. Tens of thousands of clinical trials are held in the U.S. each year but they are routinely delayed because of enrollment issues. CureLauncher's database cuts out the delay by connecting sick people with cutting-edge treatments.
"In the last year we have signed worldwide master service agreements with four of the largest pharmaceutical companies and clinical research organizations around the world," Goldner says.
That has allowed CureLauncher to hire five people over the last year, and it's currently looking to hire three more. The relationship managers help prospective patients calling into CureLauncher's offices to find the best clinical trials. The two-year-old startup now has a staff of 14 employees and two summer interns.
Source: Steve Goldner, chairman & CEO of CureLauncher
Writer: Jon Zemke
Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.